Skip to content Skip to navigation

Dominion Diagnostics celebrates 15 years

February 22, 2012
by News release
| Reprints

Dominion Diagnostics, LLC, a national medication and substance use monitoring company, is celebrating its 15th year in business providing monitoring services, clinical support and education to improve patient outcomes in addiction treatment and pain management. 

"It is a privilege to lead our company in its fifteenth year of service," said Robert Garvey, Dominion's Chief Executive Officer.  "We look forward to many more years of advancing clinical diagnostic solutions for our clients and improving the quality of life for their patients and families."

Dominion Diagnostics began in 1997 with three employees. Today, the company has hundreds of employees with laboratory locations in North Kingstown, Rhode Island and Williston, Vermont, and service centers in a variety of states. Dominion Diagnostics provides its services to thousands of patients and clinicians in the United States each year.  

Over the past 15 years, Dominion Diagnostics' mission has been to provide quality care built on a foundation of compliance, integrity, compassion, consistency, innovation, and reliability.  Dominion Diagnostics has become a trusted monitoring partner offering state of the art science, a robust suite of service offerings, customized monitoring solutions and excellent customer service that meets the unique needs of its loyal client base across the country.

Since 2004, Dominion Diagnostics has maintained a Compliance Program that mirrors the recommendations contained in the Office of the Inspector General's Compliance Program Guidance for Clinical Laboratories.  Dominion's early adoption of the optimal combination of laboratory technologies—both quantitative enzyme immunoassay (EIA) and ultra performance liquid chromatography/tandem mass spectrometry (UPLC/MS/MS)—has redefined what clinicians consider "state of the art" in monitoring.

Further, Dominion's innovative data solutions and clinical reporting tools, Scientifically Accurate Medication Monitoring (SAMM)(TM) and Comprehensive Analysis of Reported Drugs (CARD)(TM), have raised the standard for laboratories providing monitoring services and outcome assessment.

"As the healthcare system continues to evolve, Dominion Diagnostics remains committed to investing in new products and services to make practitioners' lives easier and patients' lives healthier," Garvey says.  "Our focus continues to be to improve patient care by providing access to cost-effective, evidence based treatment solutions."

Topics